AI-ACCELERATED DRUG DISCOVERY

Focused On-demand Library for Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha

Available from Reaxense
Predicted by Alphafold

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.

Our selection of compounds is from a large virtual library of over 60 billion molecules. The production and distribution of these compounds are managed by our partner Reaxense.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

Our high-tech, dedicated method is applied to construct targeted libraries for enzymes.

 Fig. 1. The sreening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.

Several key aspects differentiate our library:

  • Receptor.AI compiles an all-encompassing dataset on the target protein, including historical experiments, literature data, known ligands, and structural insights, maximising the chances of prioritising the most pertinent compounds.
  • The platform employs state-of-the-art molecular simulations to identify potential binding sites, ensuring the focused library is primed for discovering allosteric inhibitors and binders of concealed pockets.
  • Over 50 customisable AI models, thoroughly evaluated in various drug discovery endeavours and research projects, make Receptor.AI both efficient and accurate. This technology is integral to the development of our focused libraries.
  • In addition to generating focused libraries, Receptor.AI offers a full range of services and solutions for every step of preclinical drug discovery, with a pricing model based on success, thereby reducing risk and promoting joint project success.

partner

Reaxense

upacc

O00443

UPID:

P3C2A_HUMAN

Alternative names:

Phosphoinositide 3-kinase-C2-alpha

Alternative UPACC:

O00443; B0LPH2; B4E2G4; Q14CQ9

Background:

Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha, also known as Phosphoinositide 3-kinase-C2-alpha, plays a pivotal role in cellular processes including insulin signaling, glucose uptake, and vesicle trafficking. It generates crucial second messengers, PtdIns3P and PtdIns(3,4)P2, influencing various intracellular pathways.

Therapeutic significance:

Linked to Oculoskeletodental syndrome, this protein's dysfunction reveals its critical role in human health. Understanding the role of Phosphatidylinositol 4-phosphate 3-kinase C2 domain-containing subunit alpha could open doors to potential therapeutic strategies for this and related disorders.

Looking for more information on this library or underlying technology? Fill out the form below and we'll be in touch with all the details you need.
Thank you! Your submission has been received!
Oops! Something went wrong while submitting the form.